



# FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400  
AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

WRITER'S INTERNET ADDRESS:  
MGARRETT@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:  
512/418-3031

August 28 2000

FILE: UTKO:002

## CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Box Missing Parts, Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

August 28, 2000

Date

Mark T. Garrett

Assistant Commissioner for Patents  
Washington, DC 20231

RE: S/N 09/496,243 – “WOVEN INTRAVASCULAR DEVICES AND METHODS FOR  
MAKING THE SAME AND APPARATUS FOR DELIVERY OF THE SAME” –  
Hideki Hyodoh et al. (MDA98-021)

Sir:

Enclosed for filing in the above-referenced patent application is a Second Supplemental Information Disclosure Statement, Form PTO-1449, an International Search Report dated July 26, 2000 and references (A42 and B4-B9).

No fees are believed to be due in connection with the filing of this Second Supplemental Information Disclosure however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/10019614/MTG.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Mark T. Garrett  
Reg. No. 44,699  
MTG/ms  
Enclosures

RECEIVED  
SEP 12 2000  
TC 3700 MAIL ROOM



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hideki Hyodoh *et al.*

Serial No.: 09/496,243 ✓

Filed: February 1, 2000

For: WOVEN INTRAVASCULAR DEVICES AND  
METHODS FOR MAKING THE SAME AND  
APPARATUS FOR DELIVERY OF THE  
SAME


Group Art Unit: 3731

Examiner: Unknown

Atty. Dkt. No.: UTKO:002/MTG

TC 3700  
SEP 12 2000  
MAIL  
0001

RECEIVED  
RJG

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:	
8/28/00 Date	 Mark T. Garrett

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully  
requested that this Second Supplemental Information Disclosure Statement be entered and the  
documents listed on attached Form PTO-1449 be considered by the Examiner and made of

record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Second Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.98 (a)(3), a concise explanation of the relevance of reference B4 (which is written in German), as it is presently understood, is supplied below. The following statement is taken from the European Patent Office at <http://ep.espacenet.com>.

Reference B4 relates to: “A known method for treating pathological body vessels is the implantation of stents (1) as an extended filament (2), by means of a catheter (22), which springs into a given form only once at the implantation site, as a result of its thermo-memory property or its elasticity. The invention relates to a new kind of stent (1), created in order to improve the flexibility and stability of the stent. This is achieved in that the stent filament or stent filaments (2,2') are present in the form of at least two opposed spirals (3,3'). The filament (2) consists of a material with high elasticity or with thermo-memory properties. The stent (1) can be covered with a structure made of pieces of fabric and/or fibres, and serves in this way as a stent grant. The new stent demonstrates high stability and flexibility. The stent can be introduced into a body vessel by means of a lumen, which essentially corresponds to the outside diameter of the filaments (2,2') forming the stent (1), by means of a catheter (22), and expands in the point of destination to a large-lumen tube-shaped implant.”

Additionally, and in accordance with 37 C.F.R. § 1.98 (a)(3), another concise explanation of the relevance of reference B4 (which is written in German), as it is presently understood, is

supplied below. The following statement is taken from the abstracts issued by Derwent World Patent Index.

Reference B4 relates to: "The stent to support pathological body and blood vessels, inserted by a catheter at an implant site, has at least two of the filaments (2, 2') in a defined condition as coils (3, 3') twisted against each other, over at least part of the stent length. The filaments are of a material with super elastic characteristics and/or a thermal memory quality, such as 'Nitinol' (RTM). The stent can be covered by an internal or external membrane of silicon, latex or a woven polyamide.

ADVANTAGE – The stent has a high stability and is easily handled. Dwg. 1/26"

The present Second Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Second Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Assistant Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10019609/MTG.

Applicants respectfully request that the listed documents be made of record in the present  
case.



FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 418-3000

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mark T. Garrett".

Mark T. Garrett  
Reg. No. 44,699  
Attorney for Applicants

Date: August 28, 2000